COVID 19: Global Capital Confidence Barometer

Responding to now, preparing for next, thinking beyond

Featured How do you find clarity in the midst of the COVID-19 crisis? 30 Mar 2020
An investor reacts as he monitors the share index in a stock market gallery

Lead through the COVID-19 crisis

We have a clear view of the critical questions and new answers required for effective business continuity and resilience.


Contact us for immediate support

Gain access to our help with crisis management, business continuity and enterprise resilience.


Are you prepared to address Tax implications of the disruption caused by COVID-19?

Assess your organisation’s preparedness on key Tax and regulatory impact areas


Download pdf

Are you asking the right questions to respond to COVID-19?

Assess your organization’s preparedness across key impact areas


Download pdf

An open letter from Carmine di Sibio, EY Global Chairman and CEO

A message of support and reassurance to our people, clients and communities.

Read more

1. How we are creating long-term value for our clients
Clients: Business woman standing factory balcony
Staff at event

Join our COVID-19 webcasts

Join EY professionals and others on our webcasts, live and on-demand, covering supply chains, employee health, public policy, risk, information security and much more.

Discover more


The better the question. The better the answer. The better the world works.

How blockchain is helping make every blood donation more effective.

Blood donations and transfusions are vital to healthcare, but tracking the journey from vein to vein in real time remains elusive.

The better the question. The better the answer. The better the world works.

Could blockchain become the lifeblood of healthcare?

Blood donation, processing, testing, distribution and transfusion is a complex, highly regulated process. Blockchain can support monitoring and traceability from donor to patient.

About 1 in 10 people entering hospitals every day need some kind of blood transfusion – they are a fundamental cornerstone of medicine. Transfusions are needed to replace the blood of those suffering from cancer or other blood diseases and replenish blood lost in serious accidents and medical procedures like childbirth or surgery.

This demand adds up. It’s estimated that, in the US alone, about 32,000 pints (18,184 litres) of blood products (red cells, platelets or plasma) are transfused every day, so keeping a reliable and steady supply of blood is critical. About 4.5 million Americans would die every year without a transfusion.

Supply lines

Donated blood makes its way to patients via complex blood supply chain networks. Especially in a large country, each unit of blood can travel thousands of miles. Units are also broken down into smaller, similarly vital medical products, such as, plasma, platelets and red blood cells.

Knowing where products are, and what condition they are in, is essential to running any supply chain, from minerals to food to consumer products. But with blood, this accountability is even more important – after all, what’s at stake is not the continuing business of impatient customers, but people’s lives. For that reason, the tracking of blood products is highly regulated.

The challenge is to make that system as effective as possible, and to make data from the full length of the supply chain more visible, to deliver even greater benefits.

Building in trust

EY Canada has been working with Canadian Blood Services (CBS) to address this challenge with a proposal to put blood records on the blockchain. The thinking was simple: if this was done effectively, we could provide near real-time visibility and traceability of blood products throughout the system.

Bag O Rh Positive Blood
The better the question. The better the answer. The better the world works.

Developing proof of concept for ‘vein-to-vein’ monitoring

Using blockchain to power a self-updating tracking platform that offers powerful insights.

Blockchain – which encodes data in a perfectly secure and transparent way – is an ideal technology to add security and visibility to the blood supply network. By providing a platform that could guarantee the visibility, security, and reliability of records from donation to transfusion, in blockchain EY teams had identified a technology that could make blood product usage data more visible and usable.

Involving personnel from both Canada and the US, and combining multiple business disciplines, EY and CBS teams worked to turn this initial idea into a robust platform that could test the theory and provide the foundations for a transformed blood system.

  • What are blockchains?

    Blockchain is a distributed infrastructure technology. It is a decentralized ledger that keeps a record of each transaction that occurs across a network, which enables a decentralized exchange of trusted data – a shared “record book”.

    Blockchains integrate information and process within and across enterprise boundaries and have the potential to streamline and accelerate business processes, increase protection against cybersecurity and reduce or eliminate the roles of intermediaries.

Putting blood on the blockchain

“Here’s how donations work. You roll up your sleeve. A blood donation service takes the blood. They ship it under strict temperature requirements to a production site. They separate it into other products. And they take it to a hospital or blood bank,” says Warren Tomlin, Digital and Innovation Leader for EY Canada. “But then they lose visibility.”

In other words, while hospitals and CBS already maintain precise records that allow them to trace a blood product back to the donor, a product’s complete path to the patient is not visible in real time to them or to others. Blockchain can make data from that path visible, while protecting the security of private information.

With this new system, when a donation occurs, the unit is scanned and all the related blood data is put on the blockchain (supported by the EY OpsChain platform). As the products from that donation move through the supply network, those products are scanned again and again, and their location and status are registered on a single, unified platform. The underpinning blockchain technology manages the integrity of this data at every stage.

Details about the blood are taken at seven key points:

  1. When the donor donates blood at a CBS collection facility
  2. When CBS performs tests on the blood, and records the results
  3. When CBS processes the blood into red blood cells, platelets and plasma
  4. When these constituent parts of the blood are stored in the CBS inventory
  5. When logistics operators transport the blood to a hospital
  6. When the hospital gives a patient a blood transfusion using the registered product
  7. When the hospital disposes of leftover blood after it is used

“Every time we get an Internet of Things (IoT) update of the temperature, it’s recorded on the blockchain. Every time we know where it is by GPS, that’s recorded on the blockchain,” says Tomlin. “If you think about blockchain and that chain of custody, we end up creating an improved audit trail for these products,” a single visible one that stretches from donor to recipient.

The data trail

Tomlin also stresses the detail and volume of data that is packed to each package of blood recorded on the blockchain. “When someone goes and gives blood, we take that unit and we scan the barcode and ‘tokenize’ the blood,” he explains. “Then we take that barcode and we put it on the blockchain. That gives us our first snowball of data — and as Canadians, we love that analogy. As that snowball rolls around in the snow it gets bigger. It picks up more snow until it becomes the base of the snowman.”

“In the same way, each unit of blood ends up accumulating lots and lots of data,” he continues. “First of all, we get your name, your age, and your ethnicity, and your blood type. That’s all saved in the blockchain. Then, as it moves through the supply chain, it rolls up more data. In the truck it picks ups data from GPS sensors. In a cooler fitted with an IoT sensor, it picks up data about temperature. All that data gets added to the snowball. And that makes tracking much easier than it is today.”

Doctor with test tube blood sample
The better the question. The better the answer. The better the world works.

Improving healthcare transparency and outcomes

Driving efficiencies to better match donors with recipients — and improve patient outcomes.

But what do you do with all this data? Better tracking of blood usage presents a huge opportunity to improve the blood system as a whole. With real-time information about blood products as they move from donation through production, testing and distribution, the blood operator can more quickly and accurately identify areas for improvement.

Blockchain can also facilitate researchers’ access to large data sets, while at the same time protecting the privacy of donors and recipients. That could allow them to correlate patient outcomes with variables such as the gender of their blood donor, or the temperature at which the products they received had been transported. In turn, researchers’ findings could inspire changes to the blood system that benefit patients.

“The work with EY has allowed CBS to imagine a very important advancement in healthcare,” says Rick Prinzen, Chief Supply Chain Officer and Vice President of Donor Relations, CBS. “Connecting donor centre donations with in-hospital transfusions and enabling hospitals to have real-time access to the whole blood component product flow and product status represents a significant advancement in driving supply chain value and improved health outcomes”.

What patterns improve supply efficiency? If issues occur with a particular batch of blood, where exactly did those issues occur, and how can they be prevented in future?

These are just a few examples of the questions that this blockchain-enabled program could answer. And better measurement of the movement and status of blood within these vast blood donation networks promises substantial potential for identifying further improvements in the efficiency of the health service as a whole, making sure that the value of donated blood goes further, and saves even more lives.

With positive health outcomes often dependent on tiny variables in how patients are treated, the increased visibility achieved by putting blood on the blockchain could make a transformative difference.

The program initially launched in trial stages, EY solution is now moving toward implementation in markets beyond Canada.

This was a test of the system’s viability. It really works. And we proved that it would really work.
Warren Tomlin
Digital and Innovation Leader for EY Canada

Building on the blockchain

Currently, EY and CBS have a proof of concept. But as the system develops, artificial intelligence and machine learning platforms could be used to analyse that data in increasingly sophisticated ways.

For CBS, putting blood on the blockchain is about making a vital health service even better for Canadians.

For blood operators globally, it’s a first look into how emerging technology can transform the way blood reaches those who need it.

For patients, it offers life-changing results.

Researcher using microscope in laboratory to look at blood sample

Discover more

EY search

Direct to your inbox

Stay up to date with our Editor's Picks newsletter. 


Featured press releases


Capital markets likely to gain momentum post the elimination of COVID-19: EY India IPO Trends Report Q1 2020

New Delhi, 27 March 2020: India recorded 10 IPOs (US$1.41b proceeds and US$1.0m median deal size) in the first quarter of 2020 with Indian stock exchanges (BSE & NSE including SMEs) ranking eighth globally in terms of number of IPOs according to EY India IPO Trends Report: Q1 2020. Consumer products and retail was the most active sector with three IPOs launched on SME markets with approx. $1m each.

27 Mar 2020 New Delhi IN

Private equity

PE/VC investments and exits decline by over 30% Y-o-Y in February 2020: IVCA-EY report

Mumbai, 16 March 2020: According to the IVCA-EY monthly PE/VC roundup, February 2020 recorded investments worth US$1.7 billion across 74 deals, with US$677 million invested as growth capital. Exits recorded US$321 million across 15 deals, with open market exits accounting for 83% of the total value of exits.

16 Mar 2020 Mumbai IN

More press releases

Start-ups are increasingly using digital technologies, analytics and social media to identify and address consumer needs

New Delhi, March 12: Indian consumers are evolving rapidly, getting closely connected, sharing more information and are becoming more demanding, at the same time, several start-ups have started mushrooming to address unmet consumer desires, states EY’s latest report ‘Incumbents to disruptors: Adopting the start-up culture for innovation’.

12 Mar 2020

Dr. Kiran Mazumdar Shaw is the EY Entrepreneur Of The Year 2019

New Delhi, 19 February 2020 – Dr. Kiran Mazumdar Shaw, Chairperson and Managing Director, Biocon, was today named the EY Entrepreneur Of The Year 2019 and will now represent India at the EY World Entrepreneur Of The Year Award (WEOY) in Monte Carlo from 4–6 June 2020.

19 Feb 2020


Who we are